A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...

One of the highlights of Eli Lilly's third-quarter results was the rapid uptake of new type 2 diabetes therapy Mounjaro, which added more than $97 million in US sales alone in what has been ...

Eli Lilly LLY-3.25%decrease; red down pointing triangle revenue surged in the latest quarter on steady sales of Mounjaro and other weight-loss treatments in its portfolio. The drug maker logged ...

To help spread the message that managing Type 2 diabetes “doesn’t have to be a solo act,” Eli Lilly, fittingly, is assembling ...

Eli Lilly is suing four telehealth companies selling compounded versions of the pharmaceutical giant's weight loss drug Zepbound and its diabetes treatment Mounjaro, the company's latest attempt ...

Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro surged in the first quarter.

Tirzepatide is the active ingredient in Lilly weight-loss drug Zepbound and the diabetes drug Mounjaro. Related Experimental Eli Lilly weight loss drug proves promising for type 2 diabetics Eli ...

Eli Lilly revenue surged in the latest quarter on steady sales of Mounjaro and other weight-loss treatments in its portfolio. The drug maker logged net income of $2.76 billion, or $3.06 a share, up ...